M. Hauschild

发表

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

P. Fasching, T. Fehm, S. Loibl, 2011, British Journal of Cancer.

Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis

T. Fehm, T. Kühn, S. Loibl, 2020, Geburtshilfe und Frauenheilkunde.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Postoperative therapy modalities for cervical carcinoma.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2006, Anticancer research.

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2014, BMC Cancer.

Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy

P. Fasching, R. Kreienberg, S. Loibl, 2011, Breast Care.

Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine

R. Railkar, K. Friese, L. Woelber, 2009, Archives of Gynecology and Obstetrics.

1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44)

M. Rezai, P. Fasching, T. Fehm, 2015 .

Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44)

M. Rezai, P. Fasching, H. Tesch, 2014, Annals of Surgical Oncology.

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

Tanja Fehm, Carsten Denkert, Peter A Fasching, 2012, The New England journal of medicine.

Elevated IL‐6 levels in the synovial fluid of osteoarthritis patients stem from plasma cells

T. Mittlmeier, M. Müller-Steinhardt, M. Hauschild, 2007, Scandinavian journal of rheumatology.

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44).

M. Rezai, P. Fasching, R. Kreienberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S4-6: Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44)

M. Rezai, P. Fasching, T. Fehm, 2010 .

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

C. Denkert, H. Tesch, S. Loibl, 2010, Breast Cancer Research and Treatment.

Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial

L. Hemkens, J. Heil, M. Regan, 2021, BMJ Open.

Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients

K. Winzer, H. Guski, J. Blohmer, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

M. Rezai, P. Fasching, R. Kreienberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

H. Tesch, S. Loibl, M. Untch, 2010, Breast Cancer Research and Treatment.

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

T. Fehm, J. Heil, T. Kühn, 2017, Breast.

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2014, BMC Cancer.

Options and limits of surgery after pre-operative chemotherapy in breast cancer.

R. Ohlinger, J. Blohmer, S. Kümmel, 2006, Anticancer research.

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

M. Rezai, P. Fasching, T. Fehm, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

J. Baselga, S. Swain, N. Masuda, 2013, Anti-cancer drugs.

Abstract PD07-02: Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results

M. Lux, M. Beckmann, P. Fasching, 2012 .

Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra

J. Baselga, S. Swain, N. Masuda, 2012 .

Safety and efficacy of first-line epirubicin-docetaxel (ED) versus epirubicin-cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC).

S. Kuemmel, J. Blohmer, W. Lichtenegger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

T. Fehm, J. Heil, T. Kühn, 2017, Breast.

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

J. Baselga, S. Swain, N. Masuda, 2013, Anti-cancer drugs.